Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 20 February 2019
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 September 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Ovarian cancer: identifying and managing familial and genetic risk (NG241)Product type:GuidanceProgramme:NICE guidelinePublished: 21 March 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 January 2024
Ovarian cancer: recognition and initial management (CG122)Product type:GuidanceProgramme:Clinical guidelineLast updated: 2 October 2023Published: 27 April 2011
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 July 2023
Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 April 2023
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2022
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2021
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 February 2019
Tests in secondary care to identify people at high risk of ovarian cancer (DG31)Product type:GuidanceProgramme:Diagnostics guidancePublished: 15 November 2017
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2016
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2013
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2013
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 May 2005Published: 22 January 2003
Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)Product type:AdviceProgramme:Evidence summaryPublished: 22 October 2013
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer TS ID 5462Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC